Partnering
Benefits of Partnering with HUYA
- First mover advantage: An unrivaled network of thousands of contacts throughout China in the biopharmaceutical industry and among university and research institute scientists
- Exclusive agreements with leading Chinese pharmaceutical and research institutions, bioparks and incubators and a growing reputation as the first point of contact
- Six strategically placed offices in Shanghai, Beijing, Chengdu, Guangzhou, Hangzhou, and Shenzhen to leverage the major hubs of biotech activity in China
- A team of world-class managers and advisors located in the US and China with significant industry and cross-cultural experience in due diligence and dealmaking
- The largest database of lead, preclinical and clinical drug candidates sourced from China that is continually evaluated and updated
- An innovative co-development model that leverages the capabilities of Chinese partners during the early stages of development and adds value at later stages
HUYA Strategic Pharmaceutical Partners
HUYA seeks global pharmaceutical partners for co-development of its in-licensed therapeutic novel drug candidates as well as for compound access collaborations, through which partners gain access to HUYA's portfolio of novel drug candidates.
As part of its compound access collaborations, HUYA identifies and presents to its partners proprietary lead, preclinical and clinical drug candidates in specific indications originating in China. In some cases, HUYA retains the opportunity to co-develop certain compounds with the pharma partner. HUYA offers efficient access to innovative therapeutic opportunities and reduces complexity in making deals in China. In addition, HUYA's partners gain access to the company's growing Chinese bioscience network comprising premier companies, universities, government research institutions and bioparks throughout the country. Current partners include Schering-Plough, Abbott, and Solvay.